Wnt activation affects proliferation, invasiveness and radiosensitivity in medulloblastoma

Journal of Neuro-Oncology

Volumn 121, Issue 1, 2015, Pages 119-127

  Salaroli, Roberta ^a   Ronchi, Alice ^a   Buttarelli, Francesca Romana ^d   Cortesi, Filippo ^a   Marchese, Valeria ^a   Della Bella, Elena ^a   Renna, Cristiano ^a   Baldi, Caterina ^d   Giangaspero, Felice ^b,c   Cenacchi, Giovanna ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Beta catenin; Medulloblastoma; Radiosensitivity; Wnt pathway

Indexed keywords

BETA CATENIN; COMPLEMENTARY DNA; KI 67 ANTIGEN; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ELECTRON MICROSCOPY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MICROSCOPY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIATION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR INVASION; WNT SIGNALING PATHWAY; ADOLESCENT; CHILD; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; GENETICS; INFANT; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESCHOOL CHILD; RADIATION DOSE; RADIATION RESPONSE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; WESTERN BLOTTING;

ADOLESCENT; BETA CATENIN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INFANT; INFANT, NEWBORN; KI-67 ANTIGEN; MEDULLOBLASTOMA; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM INVASIVENESS; NEUROGENESIS; RADIATION TOLERANCE; TRANSFECTION; WNT PROTEINS;

EID: 84921935844     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1621-0     Document Type: Article

References (30)

1. Giangaspero F, Eberhart CG, Haapasalo H, Pietsch T, Wiestler OD, Ellison DW (2007) Medulloblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavanee WK (eds) WHO classification of tumors of the central nervous system. IARC, Lyon, pp 132–140
2. Gilbertson RJ, Ellison DW (2008) The origins of medulloblastoma subtypes. Annu Rev Pathol 3:341–365
3. Gessi M, von Bueren AO, Rutkowski S, Pietsch T (2012) p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol 106:135–140
4. Gilbertson RJ (2004) Medulloblastoma: signalling a change in treatment. Lancet Oncol 5:209–218
5. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD (2011) Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 29:1408–1414
6. Pfister SM, Korshunov A, Kool M, Hasselblatt M, Eberhart C, Taylor MD (2010) Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol 120:553–566
7. Eberhart CG (2011) Molecular diagnostics in embryonal brain tumors. Brain Pathol 21:96–104
8. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ (2010) Subtypes of medulloblastoma have distinct developmental origins. Nature 468:1095–1099
9. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381–396
10. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Bäcklund ML, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM (2012) Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 123:473–484
11. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC, United Kingdom Children’s Cancer Study Group Brain Tumour Committee (2005) Beta-catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children’s Cancer Study Group Brain Tumor Committee. J Clin Oncol 23:7951–7957
12. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O (2009) Beta-catenin status in pediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218:86–94
13. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ (2006) Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24:1924–1931
14. Cimmino F, Scoppettuolo MN, Carotenuto M, De Antonellis P, Dato VD, De Vita G, Zollo M (2012) Norcantharidin impairs medulloblastoma growth by inhibition of Wnt/b-catenin signaling. J Neurooncol 106:59–70
15. Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, Ellison DW (2006) Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5:2666–2670
16. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrsić A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R (2008) Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One 3:e3088
17. Rogers HA, Miller S, Lowe J, Brundler MA, Coyle B, Grundy RG (2009) An investigation of WNT pathway activation and association with survival in central nervous system primitive neuroectodermal tumours (CNS PNET). Br J Cancer 100:1292–1302
18. Keles GE, Berger MS, Srinivasan J, Kolstoe DD, Bobola MS, Silber JR (1995) Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol Res 7:493–503
19. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M, Pals ST (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101:6122–6127
20. Salaroli R, Di Tomaso T, Ronchi A, Ceccarelli C, Cammelli S, Cappellini A, Martinelli GN, Barbieri E, Giangaspero F, Cenacchi G (2008) Radiobiologic response of medulloblastoma cell lines: involvement of beta-catenin? J Neurooncol 90:243–251
21. Albini A, Iwamoto Y, Kleinman HK et al (1987) A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239–3245
22. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ (2006) Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7:813–820
23. Peifer M, Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. Science 2000:1606–1609
24. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14:1837–1851
25. Clevers H (2006) Wnt/beta-catenin signalling in development and disease. Cell 127:469–480
26. Nager M, Bhardwaj D, Cantì C, Medina L, Nogués P, Herreros J (2012) β-catenin signalling in glioblastoma multiforme and glioma-initiating cells. Chemother Res Pract 2012:192362
27. Momota H, Shih AH, Edgar MA, Holland EC (2008) c-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene 27:4392–4401
28. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, Gurusiddappa S, Luan J, Su JM, Leung HC, Li XN (2012) Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol 14:574–583
29. Lucero OM, Dawson DW, Moon RT, Chien AJ (2010) A re-evaluation of the “oncogenic” nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep 12:314–318
30. Pöschl J, Grammel D, Dorostkar MM, Batash R, Pöschl J, Schaffer PM (2013) Constitutive activation of beta-catenin in neural progenitors results in disrupted proliferation and migration of neurons within the central nervous system. Dev Biol 374:319–332